ISSN: 2469-9764

工業化学: オープンアクセス

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • レフシーク
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • 学者の舵取り
  • ジュネーブ医学教育研究財団
  • ユーロパブ
このページをシェアする

抽象的な

Development of Combined Transdermal Patch Formulations Incorporating Salbutamol Sulfate and Ketotifen Fumarate for Respiratory Conditions

Mustafa Soylak

Salbutamol sulfate and ketotifen fumarate are widely used medications for the treatment of respiratory conditions, such as asthma and allergic rhinitis. In this study, we aimed to develop a novel combined transdermal patch formulation containing both salbutamol sulfate and ketotifen fumarate. The transdermal patch offers several advantages over conventional oral dosage forms, including improved patient compliance, sustained drug release, and reduced systemic side effects. The formulations were prepared using a blend of polymers, permeation enhancers, and drug-loaded reservoirs. Physicochemical characterization, in vitro drug release studies, and skin permeation studies were conducted to evaluate the performance of the transdermal patches. Furthermore, the stability of the formulations was assessed over a predetermined period. The results demonstrated that the developed transdermal patches exhibited sustained drug release profiles of both salbutamol sulfate and ketotifen fumarate, and demonstrated satisfactory permeation through the skin. The stability studies revealed that the formulations maintained their integrity and drug content throughout the storage period. These findings suggest that the developed combined transdermal patch formulation has the potential to provide a convenient and effective treatment option for respiratory conditions.